Literature DB >> 15457359

Hepatitis C virus infection is a risk factor for tumor recurrence after resection of small hepatocellular carcinomas.

Teh-Ia Huo1, Jaw-Ching Wu, Cheng-Yuan Hsia, Gar-Yang Chau, Wing-Yiu Lui, Yi-Hsiang Huang, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee.   

Abstract

Hepatocellular carcinoma (HCC) is closely associated with chronic hepatitis B or C virus (HBV, HCV) infection. Tumor recurrence frequently occurs after surgical resection and may adversely affect the outcome. This study aimed to investigate the effect of viral hepatitis in association with HCC recurrence after resection. A total of 248 patients [HBV in 165, HCV in 44, dual HBV+HCV in 15, and non-B non-C (NBNC) in 24] who underwent curative resection for HCC were included. The cumulative recurrence rate was compared according to the etiology of the underlying hepatitis and was stratified by tumor size and other clinicopathologic parameters. Altogether, 116 patients (47%) had a tumor recurrence within 17 +/- 11 months after resection. No significant difference in recurrence was noted among the four groups of patients (HBV, HCV, HBV+HCV, NBNC) ( p = 0.248). Persistent hepatitis was more common in the HCV group ( p < 0.001) after resection. Among the 157 patients with a small (= 5 cm) tumor, the recurrence rate was significantly higher in the HCV group than in the HBV, HBV+HCV, and NBNC groups ( p = 0.036). Cox multivariate analysis showed that HCV infection [relative risk (RR) 4.4, 95% confidence interval (CI) 1.3-14.8, p = 0.018] and vascular invasion (RR 3.2, 95% CI 1.2-8.9, p = 0.044) were independent predictors of tumor recurrence. Stratified analysis in other parameters did not show significant differences in terms of tumor recurrence among the four virologic groups ( p > 0.1 for all parameters). In conclusion, patients with small HCCs and concurrent HCV infection are at a high risk of tumor recurrence after resection.

Entities:  

Mesh:

Year:  2004        PMID: 15457359     DOI: 10.1007/s00268-004-7320-9

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  38 in total

1.  Interferon: benefit beyond hepatitis therapy?

Authors:  D B Mallat; H B El-Serag
Journal:  Am J Gastroenterol       Date:  2001-12       Impact factor: 10.864

Review 2.  Prognostic prediction and treatment strategy in hepatocellular carcinoma.

Authors:  Jordi Bruix; Josep M Llovet
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

3.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

4.  Influence of associated viral hepatitis status on recurrence of hepatocellular carcinoma after hepatectomy.

Authors:  S Ko; Y Nakajima; H Kanehiro; T Kin; Y Aomatsu; A Yoshimura; J Taki; K Yagura; K Ohashi; H Nakano
Journal:  World J Surg       Date:  1996-10       Impact factor: 3.352

Review 5.  Pathogenesis of primary hepatocellular carcinoma.

Authors:  G W Curry; A D Beattie
Journal:  Eur J Gastroenterol Hepatol       Date:  1996-09       Impact factor: 2.566

6.  Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial.

Authors:  C L Lai; J Y Lau; P C Wu; H Ngan; H T Chung; S J Mitchell; T J Corbett; A W Chow; H J Lin
Journal:  Hepatology       Date:  1993-03       Impact factor: 17.425

7.  Hepatocellular carcinoma in Austria: aetiological and clinical characteristics at presentation.

Authors:  M Schöniger-Hekele; C Müller; M Kutilek; C Oesterreicher; P Ferenci; A Gangl
Journal:  Eur J Gastroenterol Hepatol       Date:  2000-08       Impact factor: 2.566

8.  Acute hepatitis C virus (HCV) infection in chronic carriers of hepatitis B virus (HBV): the impact of underlying active HBV replication on persistence of HCV infection and antibody responses to HCV.

Authors:  C-M Chu; C T Yeh; I S Sheen; Y F Liaw
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

9.  Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma.

Authors:  P Paterlini; K Poussin; M Kew; D Franco; C Brechot
Journal:  Hepatology       Date:  1995-02       Impact factor: 17.425

10.  Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis.

Authors:  T I Huo; J C Wu; P C Lee; G Y Chau; W Y Lui; S H Tsay; L T Ting; F Y Chang; S D Lee
Journal:  Hepatology       Date:  1998-07       Impact factor: 17.425

View more
  8 in total

1.  Characteristics of hepatocellular carcinoma nodules newly detected by computed tomography during arteriography and arterial portography: preliminary report of a randomized controlled trial.

Authors:  Takamasa Ohki; Ryosuke Tateishi; Masaaki Akahane; Shuichiro Shiina; Noriyo Yamashiki; Shintaro Mikami; Kenichiro Enooku; Eriko Goto; Ryota Masuzaki; Yuji Kondo; Tadashi Goto; Shinichi Inoo; Kuni Ohtomo; Masao Omata; Haruhiko Yoshida; Kazuhiko Koike
Journal:  Hepatol Int       Date:  2011-08-31       Impact factor: 6.047

2.  Impact of serum vascular endothelial growth factor on prognosis in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization.

Authors:  Jian-Hai Guo; Xu Zhu; Xiao-Ting Li; Ren-Jie Yang
Journal:  Chin J Cancer Res       Date:  2012-03       Impact factor: 5.087

3.  Transplant versus resection for the management of hepatocellular carcinoma meeting Milan Criteria in the MELD exception era at a single institution in a UNOS region with short wait times.

Authors:  Malcolm H Squires; Steven I Hanish; Sarah B Fisher; Cristen Garrett; David A Kooby; Juan M Sarmiento; Kenneth Cardona; Andrew B Adams; Maria C Russell; Joseph F Magliocca; Stuart J Knechtle; Charles A Staley; Shishir K Maithel
Journal:  J Surg Oncol       Date:  2013-12-17       Impact factor: 3.454

4.  Dual hepatitis B and C-associated hepatocellular carcinoma: clinical characteristics, outcome, and prognostic role of albumin-bilirubin grade.

Authors:  Chih-Chieh Ko; Shu-Yein Ho; Po-Hong Liu; Chia-Yang Hsu; Cheng-Yuan Hsia; Yi-Hsiang Huang; Chien-Wei Su; Hao-Jan Lei; Rheun-Chuan Lee; Ming-Chih Hou; Teh-Ia Huo
Journal:  Int J Clin Oncol       Date:  2022-02-04       Impact factor: 3.402

Review 5.  Influence of viral hepatitis status on prognosis in patients undergoing hepatic resection for hepatocellular carcinoma: a meta-analysis of observational studies.

Authors:  Yanming Zhou; Xiaoying Si; Lupeng Wu; Xu Su; Bin Li; Zhiming Zhang
Journal:  World J Surg Oncol       Date:  2011-09-21       Impact factor: 2.754

6.  Impact of antiviral therapy with nucleos(t)ide analog on survival of patients with HBV-related small hepatocellular carcinomas.

Authors:  Yanyan Wei; Yongxiang Yi; Chen Tao; Wei Ye; Wei Zhao
Journal:  Cancer Manag Res       Date:  2019-09-17       Impact factor: 3.989

7.  APEX1 is a novel diagnostic and prognostic biomarker for hepatocellular carcinoma.

Authors:  Lei Cao; Hongwei Cheng; Qiuxia Jiang; Hui Li; Zhixian Wu
Journal:  Aging (Albany NY)       Date:  2020-03-13       Impact factor: 5.682

8.  Chronic viral hepatitis and hepatocellular carcinoma.

Authors:  Yagil Barazani; Jonathan R Hiatt; Myron J Tong; Ronald W Busuttil
Journal:  World J Surg       Date:  2007-06       Impact factor: 3.282

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.